Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs
admin 4th September 2018 Uncategorised 0Just one week after England’s National Institute for Health and Care Excellence (NICE) said no to Gilead’s CAR-T treatment Yescarta in non-Hodgkin lymphoma, it has decided that Merck’s blockbuster checkpoint inhibitor, Keytruda, is not a good treatment choice in Hodgkin lymphoma—at least not for all patients.
More: Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs
Source: fierce